Tumoral melanosis associated with combined BRAF/ MEK inhibition (dabrafenib/trametinib) in metastatic melanoma

JAAD Case Rep. 2018 Oct 10;4(9):921-923. doi: 10.1016/j.jdcr.2018.06.024. eCollection 2018 Oct.

Authors

Antonia Laino¹, Benjamin Shepherd², Victoria Atkinson³, Hong Fu³, H Peter Soyer^{1

4}, Helmut Schaider^{1

4}

Affiliations

¹ Dermatology Research Centre, The University of Queensland, The University of Queensland Diamantina Institute, Brisbane, Australia.
² Department of Pathology, Princess Alexandra Hospital, Brisbane, Australia.
³ Department of Medical Oncology, Princess Alexandra Hospital, Brisbane, Australia.
⁴ Department of Dermatology, Princess Alexandra Hospital, Brisbane, Australia.

No abstract available

Keywords: BRAF; MEK; dabrafenib; melanoma; metastatic; regression; trametinib; tumoral melanosis.

Publication types

Case Reports